IOVANCE (NASDAQ: IOVA) CFO awarded 132,200 RSUs in equity grant

Rhea-AI Filing Summary

Roche Corleen M. reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Financial Officer, Corleen M. Roche, received a grant of 132,200 restricted stock units (RSUs) on common stock as equity compensation. Each RSU represents the right to receive one share of common stock if vesting conditions are met.

These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date. The remaining RSUs then vest in eight equal quarterly installments over the following two years, provided she remains employed with the company on each vesting date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Roche Corleen M.

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	132,200	$0.00	--

Holdings After Transaction: Restricted Stock Units — 132,200 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Roche Corleen M.

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/09/2026		A		132,200		(2)	(2)	Common stock	132,200	$0.00	132,200	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

2. Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.

	/s/ Corleen Roche	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did IOVANCE BIOTHERAPEUTICS (IOVA) report for Corleen M. Roche?

IOVANCE BIOTHERAPEUTICS reported that Chief Financial Officer Corleen M. Roche received a grant of 132,200 restricted stock units. These RSUs are part of her equity compensation and convert into common shares only if specified service-based vesting conditions are satisfied over time.

How many restricted stock units did the IOVA CFO receive in this Form 4 filing?

The CFO of IOVANCE BIOTHERAPEUTICS received 132,200 restricted stock units. Each RSU represents a right to receive one share of common stock, subject to vesting requirements tied to continued employment with the company over a three-year period.

How do the 132,200 RSUs granted to IOVA’s CFO vest over time?

The 132,200 RSUs vest over three years. One-third vests on the first anniversary of the grant date, while the remaining two-thirds vest in eight equal quarterly installments during the following two years, assuming the executive remains employed on each vesting date.

What does each restricted stock unit represent in the IOVA Form 4 for Corleen M. Roche?

Each restricted stock unit represents a contingent right to receive one share of IOVANCE BIOTHERAPEUTICS common stock. The shares are delivered only if the vesting schedule is satisfied, meaning continued employment through the specified anniversary and quarterly vesting dates.

Is the RSU grant to IOVANCE BIOTHERAPEUTICS’ CFO an open-market purchase or a compensation award?

The RSU grant is a compensation award, not an open-market purchase. It was reported with transaction code “A,” indicating a grant or award, and carries no purchase price, reflecting equity-based compensation tied to continued service rather than a cash investment.

What ownership position does the IOVA Form 4 show after the RSU grant to the CFO?

After the transaction, the Form 4 shows 132,200 restricted stock units held directly by the CFO. These units convert into an equal number of common shares only as they vest under the three-year schedule based on her continued employment with the company.